Outpatient treatment of deep vein thrombosis: translating clinical trials into practice (Q33667203)

28 July 2017

1 reference

title

Outpatient treatment of deep vein thrombosis: translating clinical trials into practice (English)

1 reference

28 July 2017

1 reference

1 reference

Dunn AS

1

1 reference

PubMed ID

10378625

28 July 2017

Coller B

series ordinal

2

1 reference

PubMed ID

10378625

28 July 2017

language of work or name

English

0 references

publication date

1 June 1999

1 reference

American Journal of Medicine

28 July 2017

1 reference

28 July 2017

106

1 reference

28 July 2017

6

1 reference

28 July 2017

660-669

1 reference

Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy?

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Usefulness of thrombelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Heparin and dextran sulfate antagonize PGI2 inhibition of platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Effect of Heparin and Heparin Fractions on Platelet Aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Regression of deep vein thrombosis by i.v.-administration of a low molecular weight heparin--results of a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Binding and endocytosis of heparin by human endothelial cells in culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Low-molecular-weight heparin in the treatment of patients with venous thromboembolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Delayed elimination of enoxaparine in patients with chronic renal insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Thromboembolic prophylaxis with low molecular weight heparin during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Reversal of low-molecular-weight heparin anticoagulation by synthetic protamine analogues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either logiparin® (LMWH) or unfractionated heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Comparative effects of heparin and LMW heparin on hemostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Ex vivo activity of heparin is not predictive of blood loss after neutralization by protamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Low-molecular-weight heparin in extracorporeal circulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

A fatal low-molecular-weight heparin-associated thrombocytopenia after hip surgery: possible usefulness of PF4-heparin ELISA test.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Heparin-induced thrombocytopenia with thrombotic complications during prophylactic treatment with low-molecular-weight heparin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Low-molecular-weight heparin--an opportunity for home treatment of venous thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

General internal medicine update. Information clinicians and teachers need to know

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Use of low-molecular-weight heparin in the treatment of venous thromboembolic disease: answers to frequently asked questions. The Thrombophilia Center Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Low-molecular-weight heparins in the treatment of venous thromboembolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Deep venous thrombosis: thinking inside out

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Stroke treatment: promising but still struggling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

Pharmacy-managed program for home treatment of deep vein thrombosis with enoxaparin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900129-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(99)00129-1

1 reference

28 July 2017

1 reference

PubMed ID

10378625